Laboratory of Pathology

Chief
Kenneth Aldape, M.D.
Deputy Chief
Frederic G. Barr, M.D., Ph.D.

The Laboratory of Pathology (LP) at the National Cancer Institute (NCI) is an integral component of the research and clinical community at the National Institutes of Health (NIH). Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education.

Diagnostics
We take responsibility for Anatomic Pathology services for the NIH as well as others who seek our expertise through consultation. Our goal is to provide the most accurate diagnostic interpretation in the most efficient manner, supported by a commitment to quality improvement.

Laboratory of Pathology Clinical Services
NIH clinical and research staff can access information about LP's Clinical Services via the internal portal 
by using NIH login credentials here: 
Link to the Laboratory of Pathology's Clinical Webpages

This site includes information about: test menus and services provided; specimen collection and submitting guidelines; accreditation and regulatory compliance; quality management; safety and infection control; emergency management; and, technical and administrative policies and procedures. 

Public Access
The general public can access information about each of the clinical sections by selecting the links below:

Education
Through the training of residents and fellows in diagnostics and research, LP's Training Programs create future leaders in clinical and experimental pathology. As an organization, we share our expertise and teaching with the clinical and scientific community.

Research
We support the research mission of the NCI and the NIH by: - investigating the biology and genetics of cancer and other diseases - developing and applying leading edge technology to diagnostic pathology - providing collaborative support for clinical research protocols In this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles. For general information about the research programs and their staff, please select the "PI & Key Staff" tab above. More detailed information about selected research programs can be viewed at:

                                                                        Laboratory of Pathology 2019

Laboratory of Pathology Staff - 2019

Hao-Wei Wang, M.D., Ph.D.
Assistant Research Physician
Constance M. Yuan, M.D., Ph.D.
Associate Research Physician
Position Keywords Contact Name Contact E-mail Number of Positions
Postdoctoral Fellow- Molecular oncology

Molecular oncology

Frederic Barr

barrfg@mail.nih.gov

1
Postdoctoral Fellow - Computational and Statistical Cancer Genomics

Computational and Statistical Cancer Genomics

Hye-Jung Chung

hjchung@mail.nih.gov

Multiple Positions Available
Postdoctoral Fellow - Cancer Genomics and Epigenomics

Cancer Genomics and Epigenomics

Hye-Jung Chung

hjchung@mail.nih.gov

1


Laboratory of Pathology Training and Fellowship Programs

Anatomic pathology slides

Anatomic Pathology Residency Training Program


The Laboratory of Pathology (LP) offers a multifaceted ACGME-accredited residency training program in Anatomic Pathology at the NIH Clinical Center. The Clinical Center is the site of intramural clinical research for the NIH, and home to more than 1500 clinical research protocols. Excelling in both clinical diagnosis and translational research, the department provides a stimulating intellectual environment for the resident interested in an academic career. The department emphasizes excellence in diagnosis and the use of modern technological tools to enhance accuracy and decipher disease mechanisms. In addition, LP staff members receive a large number of cases in consultation each year, resulting in a rich and diversified exposure to the practice of anatomic pathology. Most successful applicants have had prior research experience, or have a Ph.D. degree. Clinical training in the Anatomic Pathology Program includes three years of rotations and subspecialty training. An optional fourth year of training may be available to selected residents during which time they may participate in additional research activities. Read more...

Reactive squamous cells

Cytopathology Fellowship


The Cytopathology Section of the National Cancer Institute provides diagnostic cytopathology services to the National Institutes of Health (NIH) and its associated clinical services in the NIH Clinical Center, a 240-bed and 82 day-hospital stations research hospital. The relatively high frequency of pathologic findings combined with the diversity of types of exfoliative and fine needle aspiration (FNA) specimens seen in our Section provide a broad experience in diagnostic cytopathology. The goals of the fellowship are to develop a strong foundation in diagnostic cytopathology and introduce clinically oriented physicians to current research techniques. Read more...

Blood cells

Hematopathology Fellowship


The Hematopathology Section of the Laboratory of Pathology, National Cancer Institute, offers a fully ACGME-accredited fellowship in hematopathology, which provides broad exposure to the diagnostic and investigative aspects of neoplastic hematopathology. Material is derived principally from an active in-house treatment program for both adult and pediatric hematologic malignancies. In addition, approximately over 2000 challenging cases are submitted in consultation each year. The Hematopathology Section collaborates with the Clinical Services of the NCI, NHLBI, and NIAID in both clinical management and research. Read more...

Collage of pathology slides

Pathology Research Fellowships


Pathology research fellowship positions are available in the Laboratory of Pathology for physicians who have recently completed a pathology residency program. This fellowship is intended to give pathologists sustained and focused training in an investigative area in either basic, translational or clinical science in preparation for a career in academic pathology. This research training will initially be for one year with possible renewal for additional years depending on the fellow’s progress and the availability of positions. If the applicant is planning on pursuing subspecialty clinical fellowship training, this research training can be pursued either before or after the clinical fellowship. Available research programs include cancer genomics, cancer epigenetics, cancer-associated rearrangements, lymphoid neoplasms, brain tumors, circulating tumor DNA, liver disease, and applications of protein and genetic markers in the diagnosis, prognosis, and management of cancer. Interested candidates must have a medical degree (M.D. or equivalent) and must have completed a residency program in anatomic pathology (AP) and/or clinical pathology (CP), either in the United States or abroad. To apply, candidates should send a curriculum vitae, including a list of publications, a cover letter, and the names and contact information of three references to Frederic G. Barr, M.D. Ph.D., Deputy Chief, Laboratory of Pathology at barrfg@mail.nih

Microarray

Cancer Genomics Pathology Research Fellowships


Research fellowship positions in the area of cancer genomics pathology are available in the Laboratory of Pathology for physicians who have recently completed a pathology residency program. This research fellowship is intended to give pathologists sustained and focused training in cancer genomics in preparation for a career in academic pathology. Though this training is not eligible for board certification, the program will include time on the clinical cancer genomics service as well as substantial time in the areas of assay development and cancer genomic research applications. The Laboratory of Pathology is making a substantial investment in next-generation sequencing of solid tumors, including panel testing and whole-exome sequencing. Array-based testing for copy number and DNA methylation interrogation is also being implemented. These testing programs will provide a rich resource for exposure in state-of-the art clinical cancer genomics and will also dovetail with research opportunities. This training will initially be for one year with possible renewal for additional years depending on the fellow’s progress and the availability of positions. If the applicant is planning on pursuing subspecialty clinical fellowship training, this research training can be pursued either before or after the clinical fellowship. Interested candidates must have a medical degree (M.D. or equivalent) and must have completed a residency program in anatomic pathology (AP) and/or clinical pathology (CP), either in the United States or abroad. To apply, candidates should send CV including list of publications, cover letter, and names/contact information of three references to Frederic G. Barr, M.D., Ph.D., Deputy Chief, Laboratory of Pathology at barrfg@mail.nih.gov

Dr. Sarah Alghamdi Cytopathology Clinical Fellow 2015-2016

 

Dr. Giorgi Berulava Cytopathology Clinical Fellow 2016-2017

 

Dr. Neda Mirzamani Cytopathology Clinical Fellow 2017-2018

 

Dr. Sun A. Kim Chief Resident 2015-2018

 

Dr. Yi-Shan Lee Cytopathology Clinical Fellow 2013-2014

 

Dr. Jennifer Dreiling Chief Clinical Resident / Cytopathology Fellow 2011-2014 / 2014-2015

 

Dr. G. Tom Brown Clinical Resident 2013-2016

 

Dr. Alessio Giubellino Clinical Resident 2013-2016

 

Dr. Hao-Wei Wang Chief Resident / Hematopathology Fellow 2013-2016 / 2016-2018

 

Dr. Michael Allgaeuer Chief Resident 2014-2017

 

Dr. Drew Pratt Clinical Resident 2014-2017

 

Dr. Mary Eid Clinical Resident 2014-2017

 

Dr. Kelly Brenan Clinical Resident 2015-2018

 

Dr. Christopher Trindade Clinical Resident 2015-2018

 

Dr. Stephanie Barak Clinical Resident 2008-2011

 

Dr. Edgardo Parrilla-Castellar Clinical Resident 2008-2011

 

Dr. Fatima (Zee) Aly Clinical Resident 2008-2011

 

Dr. Sinchita RoyChowdhurit Clinical Resident 2007-2010

 

Dr. Steven White Chief Resident 2007-2010

 

Dr. Jason Hipp Clinical Resident 2007-2010

 

Dr. Deqin Ma Clinical Resident 2006-2009

 

Dr. Haresh Mani Chief Resident 2006-2009

 

Dr. Qingyan Liu Clinical Resident 2006-2009

 

Dr. Charles Bechert Clinical Resident 2005-2008

 

Dr. George Miles Chief Resident 2005-2008

 

Dr. Kant Matsuda Clinical Resident 2005-2008

 

Dr. Katherine Calvo Clinical Resident 2003-2006

 

Dr. Dorkina Myrick Clinical Resident Grad 2005

 

Dr. Andrew Feldman Clinical Resident Grad 2004

 

Dr. Jeffrey Schrager Clinical Resident Grad. 2002

 

Dr. David Berman Clinical Resident Grad. 2002

 

Dr. Stephen Hewitt Clinical Resident Grad. 2000

 

Dr. Martha Quezado Clinical Resident Grad. 1998

 

Dr. David Kleiner Clinical Resident

 


Updates from the Laboratory of Pathology

Check back for occasional news from NCI's Laboratory of Pathology.


LP Designated as Laboratory for NCI-MATCH

October 30, 2019

The Laboratory of Pathology has been accepted as an NCI-MATCH Designated Laboratory. The NCI-MATCH (EAY131) phase 2 precision medicine clinical trial (NCT02465060) is evaluating the effectiveness of treatment that is directed by genomic profiling in patients with solid tumors, lymphomas or myelomas that have progressed following standard treatments expected to prolong survival, or for rare cancer types for which there is no standard treatment. Hopefully this will provide you and your patients more options or opportunities beyond your clinical studies at the CCR.

The Laboratory of Pathology, ECOG-ACRIN and the NCI-MATCH study team are collaborating to identify eligible patients for NCI-MATCH, based on genomic profiling results from the Laboratory of Pathology. Effective immediately, all our Oncomine Comprehensive Assay results are to be screening for MATCH variants (the eligibility of TSO500 assay is in review process). If a variant(s) is found to be a qualifying tumor gene variant, the variant will be sent to the MATCH study team for further review and you as an NIH clinician will received a referral letter from the Laboratory of Pathology.

To learn more about NCI-MATCH, including clinical trial sites across the country, visit www.ecog-acrin.org/nci-match-eay131 and https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match. Please contact Dr. Mark Raffeld, or Ms. Kayla O’Donnell (NCI-MATCH coordinator) if there are any questions.

 


Elaine S. Jaffe, M.D. named NIH Distinguished Investigator

October 29, 2019

Congratulations Dr. Jaffe!

Congratulations Elaine Jaffe NIH Distinguished Scientist


TruSight Oncology ~500 Gene Panel (TSO500) is now available

Kenneth Aldape, MD
October 17, 2019

I am pleased to announce a major step forward in the NCI’s Comprehensive Oncologic Molecular Pathology and Sequencing Service (NCI-COMPASS) of the Laboratory of Pathology.

Effective immediately, a new clinical molecular test, TruSight Oncology ~500 Gene Panel (TSO500) is now available on the Molecular Pathology CRIS order menu, which is relevant for a large variety of solid tumors.

The TSO500 is our next-generation sequencing (NGS) assay that analyzes cancer-relevant genes from both DNA and RNA in one integrated workflow. During library preparation, enrichment chemistry is optimized to capture nucleic acid targets from formalin-fixed, paraffin-embedded (FFPE) tissues. With simultaneous analysis of both DNA and RNA, various types of biomarkers relevant to a given tumor type (single nucleotide variants (SNVs), indels, fusions, splice variants, tumor mutation burden (TMB), and microsatellite instability (MSI)) can be assessed from the same sample in a single assay. The RNA panel uses a probe design that enables capture of both known fusions and novel fusion partners. The TSO500 panel includes 523 genes for DNA mutation detection and 55 genes for fusion and splice variant detection.

The new molecular pathology report is also incorporated with reporting software for clinical actionability as Tier levels of FDA-approved drug and clinical trials, and pathogenicity based on AMP/ASCO/CAP/ACMG guidelines.

NIH staff may access the CRIS order instructions and full gene list of TSO500 on the NCI-COMPASS webpage. Although Oncomine Assay is still available in CRIS menu for a period, for most applications, the TSO500 can replace the Oncomine Assay for all tumor types, given that it has added features including TMB score, and MSI.  In the near future, copy number variation (CNV) will be available. There will be no need to order the Oncomine assay in the future if the TSO500 panel is requested.

Please contact Dr. Liqiang Xi if there are any questions regarding this assay, or Ms. Kayla O’Donnell for question about ordering Molecular Assays.


NCI-Connections features LP's Dr. Kenneth Aldape

October 10, 2019

Why a Precise Diagnosis is Vital to Treat Brain and Spine Tumors

NCI neuropathologist Dr. Kenneth Aldape is using the latest technologies to precisely diagnose rare brain and spine tumors. He shares his techniques and why they’re important to precision medicine.
 
A precise cancer diagnosis is essential to determine the best treatment for an individual. Yet, nearly five to 10 percent of people with a brain or spine tumor receive an inaccurate diagnosis.

Most people first learn they have a tumor from their primary care doctor. They are then referred to neuro-oncologists or doctors who have expertise in their tumor type. Part of this specialized healthcare team is a neuropathologist, a doctor who examines brain and spine tumor tissue to make a precise diagnosis.

“We come up with the best definition of the tumor possible based on the specific changes we see in the tumor under the microscope,” says Kenneth Aldape, M.D., Ph.D., senior investigator and chief of the Laboratory of Pathology in the Center for Cancer Research at NCI.

Dr. Aldape studies the genomic and epigenomic alterations in brain and spine tumors – or the way genes behave and change in cancer. He characterizes the biology of specific genomic alterations and how they contribute to the development of the disease. He also studies how they impact treatment resistance of aggressive brain tumors. 

The goal of understanding these alterations is to be able to identify and better classify tumor types. “We believe that classifying brain tumors based on their biology will lead to a greater understanding of why specific tumor subtypes may be more or less sensitive to therapies,” Dr. Aldape says.

He is also pushing for precision diagnosis for patients because of the rate of diagnostic discrepancy. “We want to reduce errors because without a proper diagnosis a lot of precision medicine may not go as well as planned,” Dr. Aldape says.

Making an Accurate Diagnosis   

Dr. Aldape works on the NCI-CONNECT healthcare team to help accurately diagnose rare brain and spine tumors. “Some of these rare tumors can be challenging to diagnose because they are so rare,” Dr. Aldape says.

At NIH, all patients who visit the Neuro-Oncology Branch have their diagnosis reviewed by a neuropathologist. Dr. Aldape receives tumor tissue in the form of a tissue block or unstained slides from the hospital where a patient had his or her surgery. If a patient has not had surgery or a biopsy, he or she can consult with NIH’s neurosurgical oncology team.  Dr. Aldape examines the tissue closely under a microscope looking at alterations in the tissue. Read more...


Laboratory of Pathology's June 2019 Newsletter

Kenneth Aldape, MD
June 5, 2019

It is axiomatic that precision medicine in oncology will require advances in precision diagnostics, and advances in our understanding of tumor genomics provide a promising approach towards improvements in precision cancer diagnostics.  Individuals bearing tumors with specific molecular alterations, such as gene mutations, amplifications and translocations, and microsatellite instability can be identified using molecular diagnostic tools available in pathology departments, and recent clinical trials for molecularly targeted agents and immunotherapies have been shown to produce unprecedented extended survival in patients with molecularly-defined tumors.  While it remains to be determined whether establishing a comprehensive tumor molecular profile of the tumor improves outcome following therapy overall, the evidence to date indicates that this approach represents a promising and dynamic pathway to this goal for specific cancer subsets, and with new data and trials that emerge on an almost a weekly basis, the future remains bright in this area. Read more...


Flow Cytometry section of the Laboratory of Pathology, NCI receives an award from Wiley publishing.  

June 3, 2019

Marrow recovery and Circulating transitional B-cells in a lymphoblastic leukemia patient post CAR-T cell therapy
Image: Marrow recovery and circulating transitional B-cells in a lymphoblastic leukemia patient post CAR-T cell therapy.

The NCI LP Flow Cytometry section achieved recognition for a Top 20 Article in Cytometry Part B: Clinical Cytometry for their original work entitled, Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection”. This publication was recognized as one of the journal's top downloaded recent papers. Amongst articles published between January 2017 and December 2018, this work received some of the most downloads in the 12 months following its online publication. This original work highlighted an unusual B-cell marrow recovery response resulting in a notable population of circulating immature B-lymphocytes.  These immature B-lymphocytes, if not carefully evaluated, might be mistaken for residual B-lymphoblastic leukemia, due to their immunophenotypic features.  In fact, the presence of these cells, likely representing transitional B-cells, may reflect brisk regeneration of the B-cell compartment and bone marrow recovery  following treatment with CAR T-cell therapy.  Furthermore, the work details specific clinical flow cytometric strategies that can be used for evaluation and prevent a mis-diagnosis of B-lymphoblastic leukemia.  According to Wiley publishing, the work generated immediate impact and visibility, contributing significantly to the advancement of the field of clinical flow cytometry. 


Methylation Classifier Now in Use as a Clinical Diagnostic Tool

May 24, 2019

Methylation classifer tool: sample image of a patient’s tumor methylation results
Sample image of a patient’s results produced by the tumor methylation diagnostic tool

The NCI Laboratory of Pathology has recently begun to use a new clinically-reportable diagnostic tool that uses genome-wide DNA methylation profiling as a diagnostic for tumors of the central nervous system. The validated tool is based, in part, on data published in a recent Nature study that showed tumor methylation profiles can provide definitive evidence to complement and refine morphology-based diagnostics in tumors of the brain and spinal cord. In the study, methylation data resulted in a change in diagnosis for 129 cases (12%) of the cohort.

The NCI Laboratory of Pathology is poised to become a diagnostic reference center to implement this tool for diagnostically challenging neuropathology cases.  Going forward, it is likely that new methylation-based classifiers will emerge for additional tumor types and we are poised to lead in this area. Areas of future growth include the implementation of clinical whole-exome sequencing, RNAseq gene expression diagnostics, and a dynamic liquid biopsy program.

For more information about access to the Laboratory of Pathology's methylation diagnostic tool, please email Kayla O’Donnell.


Elaine S. Jaffe, M.D., Receives the 2019 USCAP Board's Distinguished Pathologist Award

April 11, 2019

Dr. Elaine Jaffe accepting the 2019 USCAP Distinguished Pathologist Award

Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, has received the 2019 United States and Canadian Academy of Pathology (USCAP) Board’s Distinguished Pathologist award. The award recognizes an individual for making major contributions to pathology over the years.

The Board’s Distinguished Pathologist award was established by the Board of Directors of USCAP for recognition of distinguished service in the development of the discipline of pathology. This award is presented to an individual who is recognized for making major contributions to pathology over the years.  Read more...


LP Chief Ken Aldape Participates in NCI Facebook Live Event
"Genomics: How DNA Can Inform Cancer Diagnosis and Treatment"

February 14, 2019

About

The Laboratory of Pathology (LP) at the National Cancer Institute (NCI) is an integral component of the research and clinical community at the National Institutes of Health (NIH). Our goal is to be a globally recognized center of excellence in disease research, clinical diagnostics, and pathology education. The mission of the Laboratory of Pathology is to achieve the highest level of quality in research, diagnostics, and education.

Diagnostics
We take responsibility for Anatomic Pathology services for the NIH as well as others who seek our expertise through consultation. Our goal is to provide the most accurate diagnostic interpretation in the most efficient manner, supported by a commitment to quality improvement.

Laboratory of Pathology Clinical Services
NIH clinical and research staff can access information about LP's Clinical Services via the internal portal 
by using NIH login credentials here: 
Link to the Laboratory of Pathology's Clinical Webpages

This site includes information about: test menus and services provided; specimen collection and submitting guidelines; accreditation and regulatory compliance; quality management; safety and infection control; emergency management; and, technical and administrative policies and procedures. 

Public Access
The general public can access information about each of the clinical sections by selecting the links below:

Education
Through the training of residents and fellows in diagnostics and research, LP's Training Programs create future leaders in clinical and experimental pathology. As an organization, we share our expertise and teaching with the clinical and scientific community.

Research
We support the research mission of the NCI and the NIH by: - investigating the biology and genetics of cancer and other diseases - developing and applying leading edge technology to diagnostic pathology - providing collaborative support for clinical research protocols In this endeavor, we value scientific originality, integrity, and productivity while maintaining the highest level of ethical principles. For general information about the research programs and their staff, please select the "PI & Key Staff" tab above. More detailed information about selected research programs can be viewed at:

                                                                        Laboratory of Pathology 2019

Laboratory of Pathology Staff - 2019

PI & Key Staff

Hao-Wei Wang, M.D., Ph.D.
Assistant Research Physician
Constance M. Yuan, M.D., Ph.D.
Associate Research Physician

Positions

Position Keywords Contact Name Contact E-mail Number of Positions
Postdoctoral Fellow- Molecular oncology

Molecular oncology

Frederic Barr

barrfg@mail.nih.gov

1
Postdoctoral Fellow - Computational and Statistical Cancer Genomics

Computational and Statistical Cancer Genomics

Hye-Jung Chung

hjchung@mail.nih.gov

Multiple Positions Available
Postdoctoral Fellow - Cancer Genomics and Epigenomics

Cancer Genomics and Epigenomics

Hye-Jung Chung

hjchung@mail.nih.gov

1

Training


Laboratory of Pathology Training and Fellowship Programs

Anatomic pathology slides

Anatomic Pathology Residency Training Program


The Laboratory of Pathology (LP) offers a multifaceted ACGME-accredited residency training program in Anatomic Pathology at the NIH Clinical Center. The Clinical Center is the site of intramural clinical research for the NIH, and home to more than 1500 clinical research protocols. Excelling in both clinical diagnosis and translational research, the department provides a stimulating intellectual environment for the resident interested in an academic career. The department emphasizes excellence in diagnosis and the use of modern technological tools to enhance accuracy and decipher disease mechanisms. In addition, LP staff members receive a large number of cases in consultation each year, resulting in a rich and diversified exposure to the practice of anatomic pathology. Most successful applicants have had prior research experience, or have a Ph.D. degree. Clinical training in the Anatomic Pathology Program includes three years of rotations and subspecialty training. An optional fourth year of training may be available to selected residents during which time they may participate in additional research activities. Read more...

Reactive squamous cells

Cytopathology Fellowship


The Cytopathology Section of the National Cancer Institute provides diagnostic cytopathology services to the National Institutes of Health (NIH) and its associated clinical services in the NIH Clinical Center, a 240-bed and 82 day-hospital stations research hospital. The relatively high frequency of pathologic findings combined with the diversity of types of exfoliative and fine needle aspiration (FNA) specimens seen in our Section provide a broad experience in diagnostic cytopathology. The goals of the fellowship are to develop a strong foundation in diagnostic cytopathology and introduce clinically oriented physicians to current research techniques. Read more...

Blood cells

Hematopathology Fellowship


The Hematopathology Section of the Laboratory of Pathology, National Cancer Institute, offers a fully ACGME-accredited fellowship in hematopathology, which provides broad exposure to the diagnostic and investigative aspects of neoplastic hematopathology. Material is derived principally from an active in-house treatment program for both adult and pediatric hematologic malignancies. In addition, approximately over 2000 challenging cases are submitted in consultation each year. The Hematopathology Section collaborates with the Clinical Services of the NCI, NHLBI, and NIAID in both clinical management and research. Read more...

Collage of pathology slides

Pathology Research Fellowships


Pathology research fellowship positions are available in the Laboratory of Pathology for physicians who have recently completed a pathology residency program. This fellowship is intended to give pathologists sustained and focused training in an investigative area in either basic, translational or clinical science in preparation for a career in academic pathology. This research training will initially be for one year with possible renewal for additional years depending on the fellow’s progress and the availability of positions. If the applicant is planning on pursuing subspecialty clinical fellowship training, this research training can be pursued either before or after the clinical fellowship. Available research programs include cancer genomics, cancer epigenetics, cancer-associated rearrangements, lymphoid neoplasms, brain tumors, circulating tumor DNA, liver disease, and applications of protein and genetic markers in the diagnosis, prognosis, and management of cancer. Interested candidates must have a medical degree (M.D. or equivalent) and must have completed a residency program in anatomic pathology (AP) and/or clinical pathology (CP), either in the United States or abroad. To apply, candidates should send a curriculum vitae, including a list of publications, a cover letter, and the names and contact information of three references to Frederic G. Barr, M.D. Ph.D., Deputy Chief, Laboratory of Pathology at barrfg@mail.nih

Microarray

Cancer Genomics Pathology Research Fellowships


Research fellowship positions in the area of cancer genomics pathology are available in the Laboratory of Pathology for physicians who have recently completed a pathology residency program. This research fellowship is intended to give pathologists sustained and focused training in cancer genomics in preparation for a career in academic pathology. Though this training is not eligible for board certification, the program will include time on the clinical cancer genomics service as well as substantial time in the areas of assay development and cancer genomic research applications. The Laboratory of Pathology is making a substantial investment in next-generation sequencing of solid tumors, including panel testing and whole-exome sequencing. Array-based testing for copy number and DNA methylation interrogation is also being implemented. These testing programs will provide a rich resource for exposure in state-of-the art clinical cancer genomics and will also dovetail with research opportunities. This training will initially be for one year with possible renewal for additional years depending on the fellow’s progress and the availability of positions. If the applicant is planning on pursuing subspecialty clinical fellowship training, this research training can be pursued either before or after the clinical fellowship. Interested candidates must have a medical degree (M.D. or equivalent) and must have completed a residency program in anatomic pathology (AP) and/or clinical pathology (CP), either in the United States or abroad. To apply, candidates should send CV including list of publications, cover letter, and names/contact information of three references to Frederic G. Barr, M.D., Ph.D., Deputy Chief, Laboratory of Pathology at barrfg@mail.nih.gov

Contact Info

Laboratory of Pathology
Center for Cancer Research
National Cancer Institute
Building 10, Room 2S235
Bethesda, MD 20892-1500
Ph: 301-480-5010
Anatomic Pathology Clinical & Scientific Manager
301-480-7177
LP Administrative Officer
240-760-6328
Office of the Chief Admin Asst
301-480-6286